Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03504163
Title Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.